1
|
Branigan KS, Dotta BT. Cognitive Decline: Current Intervention Strategies and Integrative Therapeutic Approaches for Alzheimer's Disease. Brain Sci 2024; 14:298. [PMID: 38671950 PMCID: PMC11048559 DOI: 10.3390/brainsci14040298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2024] [Revised: 03/14/2024] [Accepted: 03/18/2024] [Indexed: 04/28/2024] Open
Abstract
Alzheimer's disease (AD) represents a pressing global health challenge, with an anticipated surge in diagnoses over the next two decades. This progressive neurodegenerative disorder unfolds gradually, with observable symptoms emerging after two decades of imperceptible brain changes. While traditional therapeutic approaches, such as medication and cognitive therapy, remain standard in AD management, their limitations prompt exploration into novel integrative therapeutic approaches. Recent advancements in AD research focus on entraining gamma waves through innovative methods, such as light flickering and electromagnetic fields (EMF) stimulation. Flickering light stimulation (FLS) at 40 Hz has demonstrated significant reductions in AD pathologies in both mice and humans, providing improved cognitive functioning. Additionally, recent experiments have demonstrated that APOE mutations in mouse models substantially reduce tau pathologies, with microglial modulation playing a crucial role. EMFs have also been demonstrated to modulate microglia. The exploration of EMFs as a therapeutic approach is gaining significance, as many recent studies have showcased their potential to influence microglial responses. Th article concludes by speculating on the future directions of AD research, emphasizing the importance of ongoing efforts in understanding the complexities of AD pathogenesis through a holistic approach and developing interventions that hold promise for improved patient outcomes.
Collapse
Affiliation(s)
| | - Blake T. Dotta
- Behavioural Neuroscience & Biology Programs, School of Natural Science, Laurentian University, Sudbury, ON P3E2C6, Canada
| |
Collapse
|
2
|
Zhu LN, Chen D, He C. Metabolomics comparison of metabolites and functional pathways in the SH-SY5Y cell model of Parkinson's disease under PEMF exposure. Heliyon 2024; 10:e26540. [PMID: 38404789 PMCID: PMC10884933 DOI: 10.1016/j.heliyon.2024.e26540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2023] [Revised: 02/14/2024] [Accepted: 02/15/2024] [Indexed: 02/27/2024] Open
Abstract
Objective PEMF is an emerging technique in the treatment of Parkinson's disease (PD) due to its potential improvement of movement speed. The aim of this study was to investigate the metabolic profiles of pulsed electromagnetic fields (PEMFs) in an SH-SY5Y cell model of PD. Methods The SH-SY5Y cell model of PD was induced by 1-methyl-4-phenylpyridinium (MPP+). Liquid chromatography mass spectrometry (LC‒MS)-based untargeted metabolomics was performed to examine changes in the PD cell model with or without PEMF exposure. We conducted KEGG pathway enrichment analysis to explore the potentially related pathways of the differentially expressed metabolites. Results A total of 275 metabolites were annotated, and 27 significantly different metabolites were found between the PEMF treatment and control groups (VIP >1, P < 0.05), mainly including 4 amino acids and peptides, 4 fatty acid esters, 2 glycerophosphoethanolamines, 2 ceramides and 2 monoradylglycerols; among them, 12 metabolites were upregulated, and 15 were downregulated. The increased expression levels of glutamine, adenosine monophosphate and taurine were highly associated with PEMF stimulation in the PD model. The enrichment results of differentially abundant metabolite functional pathways showed that biological processes such as the mTOR signaling pathway, PI3K-Akt signaling pathway, and cAMP signaling pathway were significantly affected. Conclusion PEMFs affected glutamine, adenosine monophosphate and taurine as well as their functional pathways in an in vitro model of PD. Further functional studies regarding the biological effect of these changes are required to evaluate the clinical efficacy and safety of PEMF treatment in PD.
Collapse
Affiliation(s)
- Li-na Zhu
- Department of Rehabilitation Medicine, Key Laboratory of Rehabilitation Medicine, Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
| | - Deng Chen
- Department of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue Lane 37 #, Chengdu, 610041, Sichuan, China
| | - Chengqi He
- Department of Rehabilitation Medicine, Key Laboratory of Rehabilitation Medicine, Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
| |
Collapse
|
3
|
Barra A, Rosenfelder M, Mortaheb S, Carrière M, Martens G, Bodien YG, Morales-Quezada L, Bender A, Laureys S, Thibaut A, Fregni F. Transcranial Pulsed-Current Stimulation versus Transcranial Direct Current Stimulation in Patients with Disorders of Consciousness: A Pilot, Sham-Controlled Cross-Over Double-Blind Study. Brain Sci 2022; 12:429. [PMID: 35447961 PMCID: PMC9031379 DOI: 10.3390/brainsci12040429] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 03/09/2022] [Accepted: 03/11/2022] [Indexed: 02/01/2023] Open
Abstract
Transcranial direct-current stimulation (tDCS) over the prefrontal cortex can improve signs of consciousness in patients in a minimally conscious state. Transcranial pulsed-current stimulation (tPCS) over the mastoids can modulate brain activity and connectivity in healthy controls. This study investigated the feasibility of tPCS as a therapeutic tool in patients with disorders of consciousness (DoC) and compared its neurophysiological and behavioral effects with prefrontal tDCS. This pilot study was a randomized, double-blind sham-controlled clinical trial with three sessions: bi-mastoid tPCS, prefrontal tDCS, and sham. Electroencephalography (EEG) and behavioral assessments were collected before and after each stimulation session. Post minus pre differences were compared using Kruskal-Wallis and Wilcoxon signed-rank tests. Twelve patients with DoC were included in the study (eight females, four traumatic brain injury, 50.3 ± 14 y.o., 8.8 ± 10.5 months post-injury). We did not observe any side-effects following tPCS, nor tDCS, and confirmed their feasibility and safety. We did not find a significant effect of the stimulation on EEG nor behavioral outcomes for tPCS. However, consistent with prior findings, our exploratory analyses suggest that tDCS induces behavioral improvements and an increase in theta frontal functional connectivity.
Collapse
Affiliation(s)
- Alice Barra
- Coma Science Group, GIGA Consciousness-GIGA Research, University of Liège, 4000 Liège, Belgium; (A.B.); (S.M.); (M.C.); (G.M.); (S.L.)
- Centre du Cerveau, University Hospital of Liège, 4000 Liège, Belgium
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02114, USA; (Y.G.B.); (L.M.-Q.)
| | - Martin Rosenfelder
- Department of Neurology, Therapiezentrum Burgau, Kapuzinerstrasse 34, 89331 Burgau, Germany; (M.R.); (A.B.)
- Clinical and Biological Psychology, Institute of Psychology and Education, Ulm University, 89081 Ulm, Germany
| | - Sepehr Mortaheb
- Coma Science Group, GIGA Consciousness-GIGA Research, University of Liège, 4000 Liège, Belgium; (A.B.); (S.M.); (M.C.); (G.M.); (S.L.)
- Physiology of Cognition Lab, GIGA-Consciousness, University of Liège, 4000 Liège, Belgium
| | - Manon Carrière
- Coma Science Group, GIGA Consciousness-GIGA Research, University of Liège, 4000 Liège, Belgium; (A.B.); (S.M.); (M.C.); (G.M.); (S.L.)
- Centre du Cerveau, University Hospital of Liège, 4000 Liège, Belgium
| | - Geraldine Martens
- Coma Science Group, GIGA Consciousness-GIGA Research, University of Liège, 4000 Liège, Belgium; (A.B.); (S.M.); (M.C.); (G.M.); (S.L.)
- Centre du Cerveau, University Hospital of Liège, 4000 Liège, Belgium
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02114, USA; (Y.G.B.); (L.M.-Q.)
| | - Yelena G. Bodien
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02114, USA; (Y.G.B.); (L.M.-Q.)
- Center for Neurotechnology and Neurorecovery, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Leon Morales-Quezada
- Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02114, USA; (Y.G.B.); (L.M.-Q.)
- Neuromodulation Center, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02114, USA;
| | - Andreas Bender
- Department of Neurology, Therapiezentrum Burgau, Kapuzinerstrasse 34, 89331 Burgau, Germany; (M.R.); (A.B.)
- Department of Neurology, Ludwig-Maximilians University (LMU), 81377 Munich, Germany
| | - Steven Laureys
- Coma Science Group, GIGA Consciousness-GIGA Research, University of Liège, 4000 Liège, Belgium; (A.B.); (S.M.); (M.C.); (G.M.); (S.L.)
- Centre du Cerveau, University Hospital of Liège, 4000 Liège, Belgium
- Joint International Research Unit on Consciousness, CERVO Brain Research Centre CIUSS, University Laval, Quebec, QC G1E1T2, Canada
| | - Aurore Thibaut
- Coma Science Group, GIGA Consciousness-GIGA Research, University of Liège, 4000 Liège, Belgium; (A.B.); (S.M.); (M.C.); (G.M.); (S.L.)
- Centre du Cerveau, University Hospital of Liège, 4000 Liège, Belgium
- Neuromodulation Center, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02114, USA;
| | - Felipe Fregni
- Neuromodulation Center, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02114, USA;
| |
Collapse
|